AnnDoanBassMD

Neurology • San Antonio, TX

Neuroimmunology/Multiple Sclerosis

Neurology Center of San Antonio, PA

Join to view full profile

Dr. Bass is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Bass' full profile

Already have an account?

Office
1314 E Sonterra Blvd
Suite 601
San Antonio, TX 78258
Phone+1 210-490-0016

Fax+1 210-490-3010
Is this information wrong?

Summary

I am a board-certified neurologist specializing in the diagnosis, treatment, and management of multiple sclerosis and other CNS demyelinating diseases. I am the Medical Director of the comprehensive MS clinic at the Neurology Center of San Antonio, which is affiliated and certified by the National Multiple Sclerosis Society.

Clinical Expertise

Multiple sclerosis, Demyelinating diseases, Neuroimmunology (Multiple sclerosis)

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Neurology, 1994 - 1997
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineInternship, Internal Medicine, 1993 - 1994
The University of Texas Health Science Center at San AntonioClass of 1993

Certifications & Licensure

TX State Medical License 1995 - 2024
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Most Compassionate Doctor American Registry
Top MD Consumers Checkbook
Super Doctor SuperDoctors.com

Clinical Trials

A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2) Start of enrollment: 2019 Jul 22
Active, not recruiting
Roles: Principal Investigator
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. Start of enrollment: 2022 Jan 25
Recruiting
Phase 4
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis Start of enrollment: 2022 May 03
Active, not recruiting
Phase 3
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS Start of enrollment: 2018 Dec 28
Recruiting
Phase 3
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis Start of enrollment: 2018 May 28
Active, not recruiting
Phase 3
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) Start of enrollment: 2020 Jun 11
Active, not recruiting
Phase 3
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) Start of enrollment: 2020 Sep 24
Active, not recruiting
Phase 3
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) Start of enrollment: 2020 Aug 13
Recruiting
Phase 3
Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) Start of enrollment: 2020 Jan 16
Active, not recruiting
Phase 3
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis Start of enrollment: 2019 Nov 18
Active, not recruiting
Phase 3
A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS) Start of enrollment: 2018 Sep 14
Completed
Phase 3
An Extension of the TG1101-RMS201 Trial Start of enrollment: 2017 Jun 01
Completed
Phase 2
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) Start of enrollment: 2017 Sep 19
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

10 citations
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
Alasdair J Coles, Joanne L Jones, Patrick Vermersch, Anthony Traboulsee, Ann D Bass, Aaron Boster, Andrew Chan, Giancarlo Comi, Óscar Fernández, Gavin Giovannoni, Eva ...> ;Multiple Sclerosis. 2022 Apr 1
The sequential natalizumab - alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial - Part I: Rationale and objectives.
Rehana Z Hussain, Peter V Sguigna, Annette Okai, Crystal Wright, Mariam Madinawala, Ann D Bass, Gary R Cutter, Navid Manouchehri, Olaf Stuve> ;Journal of Central Nervous System Disease. 2022 Jan 1
9 citations
B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report.
Amy E. Lovett-Racke, Yuhong Yang, Yue Liu, Matthew Gormley, Emma E. Kraus, Calsey Graham, Sibyl Wray, Michael K. Racke, Enrique Alvarez, Ann D Bass, Edward Fox> ;Journal of Neuroimmunology. 2021 Oct 15
26 citations
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial:
Alasdair Coles, Douglas L. Arnold, Ann D Bass, Aaron Boster, D Alastair S Compston, Oscar Fernandez, Eva Havrdova, Kunio Nakamura, Anthony Traboulsee, Tjalf Ziemssen, ...> ;Therapeutic Advances in Neurological Disorders. 2021 Apr 23
6 citations
Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years.
Ann D Bass, Rafael Arroyo, Aaron Boster, Alexey Boyko, Sara Eichau, Carolina Ionete, Volker Limmroth, Carlos Navas, Daniel Pelletier, Carlo Pozzilli, Jennifer Ravenscr...> ;Multiple Sclerosis and Related Disorders. 2021 Apr 1
4 citations
Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial.
Robert A. Bermel, Emmanuelle Waubant, Gabriel Pardo, Ann D Bass, Pavle Repovic, Scott D. Newsome, J. W. Lindsey, Deidre Kile, Ashish Pradhan, B Musch, Aram Zabeti> ;Annals of Clinical and Translational Neurology. 2021 Mar 1
5 citations
CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
Augusto Miravalle, Joshua Katz, Derrick Robertson, Brooke Hayward, Danielle E. Harlow, Lori A Lebson, Jacob A. Sloane, Ann D Bass, Edward Fox> ;Neurodegenerative Disease Management. 2021 Feb 1
18 citations
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, an...
Giancarlo Comi, Raed Alroughani, Aaron Boster, Ann D Bass, Regina Berkovich, Oscar Fernandez, Ho Jin Kim, Volker Limmroth, Jan Lycke, Richard A L Macdonell, Basil Shar...> ;Multiple Sclerosis. 2020 Dec 1
31 citations
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Ext...
Tjalf Ziemssen, Ann D Bass, Regina Berkovich, Giancarlo Comi, Sara Eichau, Jeremy Hobart, Samuel F. Hunter, Christopher LaGanke, Volker Limmroth, Daniel Pelletier, Car...> ;CNS Drugs. 2020 Sep 1
16 citations
Effect of Multiple Sclerosis on Daily Activities, Emotional Well-being, and Relationships: The Global vsMS Survey.
Ann D Bass, Bart Van Wijmeersch, Lori Mayer, Mathias Mäurer, Aaron Boster, Matt Mandel, Colin P. Mitchell, Kersten Sharrock, Barry A Singer> ;International Journal of MS Care. 2020 Jul 1
25 citations
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223
Brian Steingo, Yaser Al Malik, Ann D Bass, Regina Berkovich, Matthew Carraro, Oscar Fernandez, Carolina Ionete, Luca Massacesi, Sven G. Meuth, Dimos D. Mitsikostas, Ga...> ;Journal of Neurology. 2020 Jun 24
34 citations
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Adam Cuker, Ann D Bass, Congor Nadj, Mark A Agius, Brian Steingo, Krzysztof Selmaj, Timothy Thoits, Alexandre Guerreiro, Bart Van Wijmeersch, Tjalf Ziemssen, Sven G. M...> ;Multiple Sclerosis. 2020 Jan 1
33 citations
B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients
Amy E. Lovett-Racke, Matthew Gormley, Yue Liu, Yuhong Yang, Calsey Graham, Sibyl Wray, Michael K. Racke, Richard Shubin, Cary Twyman, Enrique Alvarez, Ann D Bass, Jame...> ;Journal of Neuroimmunology. 2019 Jul 15
12 citations
Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.
Krista Barclay, Robert Carruthers, Anthony Traboulsee, Ann D Bass, Christopher LaGanke, Antonio Bertolotto, Aaron Boster, Elisabeth Gulowsen Celius, Jérôme De Seze, Di...> ;Frontiers in Neurology. 2019 Mar 22
186 citations
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial
Alasdair Coles, Edward Fox, A. Vladic, Suzanne Gazda, Vesna V. Brinar, Krzysztof Selmaj, A. Skoromets, I. Stolyarov, Adam J. Bass, H. C. Sullivan, David Margolin, Step...> ;Neurology. 2012 Apr 3
102 citations
Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes
Alasdair Coles, Edward Fox, Anton Vladic, Suzanne Gazda, Vesna V. Brinar, Krzysztof Selmaj, Ann D Bass, Daniel Wynn, David Margolin, Stephen Lake, Susan Moran, Jeffrey...> ;The Lancet. Neurology. 2011 Apr 1
Join now to see all

Abstracts/Posters

Efficacy of a fourth alemtuzumab course in RRMS patients from CARE-MS II who experienced disease activity after three prior courses
Traboulsee A, Alroughani R, Boster A, Bass A, Berkovich R, Fernandez O, Kim H-J, Limmroth V, Lycke J, Macdonell RAL, Singer BA, Vermersch P, Wiendl H, Ziemssen T, Mela..., 53rd CNSF Congress 2018, Halifax, Nova Scotia, Canada, 6/24/2018
Efficacy of a Fourth Alemtuzumab Course in RRMS Patients With Disease Activity After Three Prior Courses: Analysis of CARE-MS I
Heinz Wiendl1, Raed Alroughani2, Aaron Boster3, Anthony Traboulsee4, Ann D Bass5, Regina Berkovich6, Giancarlo Comi7, Óscar Fernández8, Ho Jin Kim9, Volker Limmroth10,..., EAN 2018, Lisbon, Portugal, 6/16/2018
Efficacy of a Fourth Alemtuzumab Course in RRMS Patients With Disease Activity After Three Prior Courses: Analysis of CARE-MS II
Barry A Singer1, Raed Alroughani2, Aaron Boster3, Ann D Bass4, Regina Berkovich5, Giancarlo Comi6, Óscar Fernández7, Ho Jin Kim8, Volker Limmroth9, Jan Lycke10, Richar..., CMSC 2018, Nashville, TN, 5/30/2018
Efficacy of Alemtuzumab Retreatment After 2 Initial Courses
Basil Sharrack1, Barry A Singer2 Aaron Boster3, Ann D Bass4, Regina Berkovich5, Giancarlo Comi6, Óscar Fernández7, Ho Jin Kim8, Volker Limmroth9, Jan Lycke10, Richard ..., 2018 Annual Conference of the Association of British Neurologists (ABN), Birmingham, United Kingdom, 5/9/2018
Efficacy of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Received Retreatment Due to Disease Activity After the Initial Two Courses: ...
Aaron Boster1, Ann D Bass2, Regina Berkovich3, Giancarlo Comi4, Óscar Fernández5, Ho Jin Kim6, Volker Limmroth7, Jan Lycke8, Richard AL Macdonell9, Basil Sharrack10, A..., AAN 2018, Los Angeles, CA, 4/21/2018
Efficacy of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Received Retreatment Due to Disease Activity After the Initial Two Courses: ...
Barry A Singer1, Aaron Boster2, Ann D Bass3, Regina Berkovich4, Giancarlo Comi5, Óscar Fernández6, Ho Jin Kim7, Volker Limmroth8, Jan Lycke9, Richard AL Macdonell10, B..., AAN 2018, Los Angeles, CA, 4/21/2018
Efficacy of a Third Course of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Experienced Disease Activity After the Initial Two Courses...
Patrick Vermersch1, Anthony Traboulsee2, Aaron Boster3, Ann D Bass4, Regina Berkovich5, Giancarlo Comi6, Óscar Fernández7, Ho Jin Kim8, Volker Limmroth9, Jan Lycke10, ..., 12th World Congress on Controversies in Neurology (CONy), Warsaw, Poland, 3/22/2018
Efficacy of Alemtuzumab Retreatment in Patients Who Experienced Disease Activity After the Initial Two Courses: Results from CARE-MS II
Aaron Boster1, Anthony Traboulsee2, Ann D Bass3, Regina Berkovich4, Giancarlo Comi5, Óscar Fernández6, Ho Jin Kim7, Volker Limmroth8, Jan Lycke9, Richard AL Macdonell1..., ACTRIMS 2018, San Diego, CA, 2/1/2018
Efficacy of a Third Course of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Experienced Disease Activity After the Initial Two Courses...
Kim H-J, Traboulsee A, Boster A, Bass A, Berkovich R, Comi G, Fernandez O, Limmroth V, Lycke J, Macdonell RAL, Sharrack B, Vermersch P, Wiendl H, Ziemssen T, Melanson ..., PACTRIMS 2017, Ho Chi Minh City, Vietnam, 11/23/2017
Efficacy of a Third Course of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Experienced Disease Activity After the Initial Two Courses...
Anthony Traboulsee, Aaron Boster, Ann D Bass, Regina Berkovich, Giancarlo Comi, Óscar Fernández, Ho Jin Kim, Volker Limmroth, Jan Lycke, Richard AL Macdonell, Basil Sh..., ECTRIMS 2017, Paris, France, 10/25/2017
Efficacy and Safety of Alemtuzumab in Patients With RRMS Is Durable Over 10 Years: Follow-up From the CAMMS223 Study
Krzysztof W Selmaj, Mario Habek, Ann Bass, David Brassat, Vesna Brinar, Alasdair J Coles, Anton Vladic, Sibyl E Wray, David H Margolin, Karthinathan Thangavelu, Madali..., AAN 2017, Boston, MA, 4/22/2017
Impact of Multiple Sclerosis on Patients’ Daily Activities, Emotional Well-Being and Relationships: Results of the Global vsMS™ Survey
Ann Bass, Bart Van Wijmeersch, Lori Mayer, Mathias Mäurer, Matt Mandel, Kersten Sharrock, Barry Singer, AAN 2017, Boston, MA, 4/22/2017
Join now to see all

Press Mentions

Merck Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022March 31st, 2022
EMD Serono Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022March 31st, 2022
Woman Learns to Embrace Life with Relapsing Multiple Sclerosis (MS)May 29th, 2019
Join now to see all